Explaining Vertical Integration in the Generic Pharmaceutical Industry

@inproceedings{Kubo2011ExplainingVI,
  title={Explaining Vertical Integration in the Generic Pharmaceutical Industry},
  author={Kensuke Kubo},
  year={2011}
}
This paper explores the motives for vertical integration in the US generic pharmaceutical industry. There is some evidence of strategic complementarity: a firm is more likely to enter a generic drug market in a vertically integrated manner if it expects a higher degree of vertical integration among rivals. This suggests that vertical integration is characterized by bandwagon behavior. While bandwagon effects have been widely discussed in the vertical integration literature, this is one of the… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 68 REFERENCES

OGD’s ANDA Backlog and Median ANDA Approval Times are Up - WAY UP! ‘The Solution Lies in Resources,

  • Karst, R Kurt
  • Says FDA Commissioner Hamburg.” FDA Law Blog
  • 2010

Preparing for Paragraph IV Patent Challenges.

  • Burck, Benjamin
  • Scrip Intelligence
  • 2010

The Impacts of the Rise of Paragraph IV Challenges on Startup Alliance Formation and Firm Value in the Pharmaceutical Industry.

  • Filson, Darren, Ahmed Oweis
  • Journal of Health Economics
  • 2010

Understanding and Using NAMCS and NHAMCS Data: Data Tools and Basic Programming Techniques.

  • Hsiao, Chun-Ju
  • Presentation Slides for the National Conference…
  • 2010

Similar Papers

Loading similar papers…